Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2002

View Archived Issues

Daiichi decides not to seek marketing approval for nefiracetam in Japan

Development of memantine in Japan extended to mild to moderate AD under new agreement

Corus receives orphan drug designation for inhaled antibiotic in CF patients

HIV entry inhibitor effective as salvage therapy in patients failing conventional treatment

Potential utility of Antrin photoangioplasty further supported by data presented during ACC meeting

Efficacy of etoricoxib significantly superior to placebo in the treatment of chronic low back pain

Prague presentations describe good anti-HBV activity and favorable pharmacokinetics of MIV-210

TAS-108, a safer antiestrogen for breast cancer

Xenova offers a profile of its achievements in 2001

Oral entecavir highly effective in transgenic mouse model of HBV infection

First oral drug developed to treat smallpox infection

Schering-Plough searches for new antibiotics using genomic-derived targets

Cell Genesys discontinues p27/p16 gene therapy collaboration

Monoclonal antibodies for treating autoimmune conditions claimed by Immunex

Schering AG to acquire Collateral Therapeutics

Scientists at Takeda present new factor Xa inhibitors

Novel GnRH antagonists for sex hormone-dependent conditions identified at GSK

Selective COX-2 inhibitors reported in a recent patent from Roche

New antiviral compounds disclosed by Bayer

GlaxoSmithKline presents new compounds for inflammatory and allergic conditions

Daclizumab fails to meet endpoint as maintenance treatment in psoriasis

Nicotinic cholinergic receptors from Targacept have potential for a wide variety of CNS disorders

Research at Corixa leads to new hepatitis B and influenza vaccines

CPMP recommends approval of Tamiflu for influenza in E.U.

FDA approval for Avinza for once-daily treatment of chronic pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...